NCT06735781 - Clinical Outcomes of Patients With Resectable Non-Small Cell Lung Cancer Receiving Neoadjuvant Nivolumab Plus Chemotherapy in France | Biotech Hunter

Enrollment

101

Participants

Timeline

Start Date

September 5, 2024

Primary Completion Date

October 1, 2024

Study Completion Date

October 1, 2024

Conditions

Non-small Cell Lung Cancer (NSCLC)

Interventions

DRUG

Nivolumab

As prescribed by the treating clinician

Trial Locations (7)

Centre François Baclesse, Caen

Centre Léon Bérard, Lyon

Hospices Civils de Lyon, Lyon

Hôpital Robert Schuman, Metz

Institut du Cancer de Montpellier, Montpellier

Institute Curie, Paris

Hôpital d'Instruction des Armées Saint Anne, Toulon